- 专利标题： METHODS FOR PREDICTING ACUTE REJECTION IN HEART RECIPIENTS
-
申请号： US15125355申请日： 2015-03-17
-
公开(公告)号： US20170130267A1公开(公告)日： 2017-05-11
- 发明人: Jean-Paul DUONG VAN HUYEN , Xavier JOUVEN , Alexandre LOUPY , Marion TIBLE
- 申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PARIS DIDEROT - PARIS 7 , UNIVERSITÉ PARIS DESCARTES , ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)
- 申请人地址： FR Paris FR Paris FR Paris FR Paris
- 专利权人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECERRCHE MEDICALE),UNIVERSITE PARIS DIDEROT - PARIS 7,UNIVERSITE PARIS DESCARTES,ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
- 当前专利权人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECERRCHE MEDICALE),UNIVERSITE PARIS DIDEROT - PARIS 7,UNIVERSITE PARIS DESCARTES,ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
- 当前专利权人地址： FR Paris FR Paris FR Paris FR Paris
- 优先权： EP14305373.4 20140317
- 国际申请： PCT/EP2015/055553 WO 20150317
- 主分类号： C12Q1/68
- IPC分类号： C12Q1/68
摘要：
The present invention relates to method for predicting acute rejection in heart recipients. In particular, the present invention relates to a method for predicting acute rejection in a heart recipient comprising the steps consisting of i) determining the expression level (ELi) of at least one miRNAi selected from the group consisting of miR-155, miR-10a, miR-92a and miR-31 in a blood sample obtained from the heart recipient, ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) and iii) and concluding that the recipient has a high risk of developing acute rejection when the level the expression level (ELi) determined at step i) is different (higher or lower) than the predetermined reference level (ELRi).